Cannabis
GB Sciences’ Chief Science Officer Featured on the Cover of the Marijuana Business Magazine
GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine. This edition (https://mjbizmagazine.com/digital-issues/2019-09-Oct/) examines the evolution of the medical marijuana market to serve the unique needs of two distinct market segments; providing: (1) disease-targeted medicines requiring federal government-approvals and (2) the burgeoning wellness market. Dr. Andrea Small-Howard, GB Sciences’ Chief Science Officer and Director, explains why GB Sciences is well-positioned to provide research-supported product formulations for both market segments.
“My hope is that there will be a stratification that serves both kinds of customers-serious medical patients and wellness patients. They’re two very different but very real customer groups,” explains Dr. Small-Howard, CSO and Director of GB Sciences. “Our research-driven approach to product development allows us to better serve both of these new market segments.”
Despite the growth of adult use markets in the US, GB Sciences is one of several companies that sees the evolution of the medical marijuana industry as an exciting opportunity. Over the past five years, GB Sciences has focused on developing a rich network of research partners and associates within a dozen universities, hospitals, and product development companies in the US and internationally. Now GB Sciences is leveraging this network and their eight patent-pending product families to create science-driven products with complex formulations and novel delivery methods to better serve the therapeutic needs of both customer groups.
“We’ve always been heading towards the creation of both US FDA-approved and branded wellness products that are more complex formulations with a scientific mindset; for example, our cannabis-based formulation to treat Parkinson’s that is now in animal trials,” relates Dr. Small-Howard. “On the wellness side, we are convinced that novel delivery systems, such as oral thin films, will allow convenient and more efficacious dosing of cannabis compounds for customers who want the therapeutic benefits of these cannabis-based ingredients.”
John Poss, CEO of GB Sciences, commenting on the article, explains another significant factor in wellness product lines: “Pharmaceuticals can take a decade or more to develop, but wellness products can help patients right now. For example, someone with Parkinson’s Disease may be aided through a wellness product designed to support sleep, or someone with PTSD may be eased with a wellness product formulated to reduce anxiety. GB Sciences is committed to taking some of our products through the US FDA, but we don’t want patients to continue to suffer while waiting for those products to be approved and available. Although our current patent applications cover formulations addressing over 60 medical conditions, we have identified three or four that are destined for the US FDA route, while many others will be developed for the health and wellness markets. These wellness products do not contain THC, which opens many distribution possibilities.”
SOURCE GB Sciences, Inc.
Cannabis
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
Cannabis
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
Cannabis
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 weeks ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace
-
SCHWAZZE2 weeks ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 weeks ago
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis5 days ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis4 days ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan4 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey